# Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases

> **NCT05054998** · PHASE4 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Brain
- Metastatic Malignant Solid Neoplasm

## Interventions

- **RADIATION:** Fludeoxyglucose F-18
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT05054998
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-03
- **Primary completion:** 2024-04-26
- **Final completion:** 2024-04-26
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05054998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05054998, "Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05054998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*